NCT07221942: Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial Carcinoma
- State
- Under way
- Phase
- Phase 2
- People
- 97 planned
- Started
- 23 Jan 2026
- Primary completion
- 1 Sep 2028
- Arms
- Induction EV + Pembrolizumab Followed by Maintenance Pembrolizumab
- Results
- None posted
- 29 Oct 2025: Trial registered
- 23 Jan 2026: Trial started